#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to understand that cancer survivors actively seek cannabis for symptom management, yet many providers lack evidence-based frameworks to discuss risks and benefits, creating a communication gap that may harm the therapeutic relationship. This disagreement between patients and providers suggests that standardized clinical guidance on cannabis counseling could improve informed decision-making and reduce patients’ reliance on non-medical sources for cannabis information. As medical cannabis legality expands, clinicians must develop competency in cannabis conversations to address patient preferences while ensuring evidence-based recommendations for symptom management in cancer survivorship care.
A recent study examining attitudes toward medical cannabis among cancer survivors and their healthcare providers reveals significant disagreement about its role in cancer care, with survivors generally more open to its use than providers. The research highlights that despite medical cannabis legality in 47 states and D.C., oncologists and other physicians often lack confidence in the evidence base or express safety concerns that differ from patient perspectives. This discordance is clinically important because provider framing and recommendations substantially influence whether patients pursue cannabis-based treatments, potentially affecting symptom management decisions for pain, nausea, and other treatment-related side effects. The gap suggests that many clinicians may not have adequate training or resources to counsel cancer survivors on cannabis use, creating a situation where patients seek information from less reliable sources. Clinicians should consider developing evidence-based conversations with cancer patients about cannabis, clarifying what evidence exists for specific symptoms while acknowledging current knowledge gaps, rather than dismissing patient interest out of hand.
“What this study highlights is a real communication gap between cancer survivors seeking symptom relief and providers like myself who are trained to be cautious about evidence levels. We have observational data and patient reports suggesting cannabis may help with chemotherapy-related nausea, pain, and sleep, but we’re still waiting for the robust randomized trials that would let me recommend it with the same confidence I do other treatments, and that gap in evidence is worth being honest about with patients rather than letting their desperation or our own uncertainty drive the conversation.”
🏥 The divergence between cancer survivors’ interest in medical cannabis and provider skepticism highlights a critical communication gap in supportive care. This disagreement likely reflects several legitimate concerns on both sides: patients may be drawn to cannabis for symptom management based on anecdotal evidence or peer experiences, while providers may hesitate due to limited robust clinical trial data, potential drug interactions with chemotherapy or supportive medications, and concerns about cognitive effects or dependence in vulnerable populations. The legality of medical cannabis in most states has outpaced high-quality evidence regarding efficacy and safety in oncology specifically, creating a vacuum where patient preferences and clinical guidance diverge. Clinically, this suggests that oncology providers should engage in proactive, non-dismissive conversations with cancer survivors about cannabis use or interest, acknowledging both the understandable appeal for symptom relief and the genuine evidentiary gaps, while documenting discussions and remaining alert to potential interactions and adverse effects
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
